<!DOCTYPE html>

<html xmlns="http://www.w3.org/1999/xhtml">

<head>

<meta charset="utf-8" />
<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
<meta name="generator" content="pandoc" />




<title>Topic III - LF1</title>

<script src="site_libs/jquery-1.11.3/jquery.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="site_libs/bootstrap-3.3.5/css/flatly.min.css" rel="stylesheet" />
<script src="site_libs/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/respond.min.js"></script>
<script src="site_libs/jqueryui-1.11.4/jquery-ui.min.js"></script>
<link href="site_libs/tocify-1.9.1/jquery.tocify.css" rel="stylesheet" />
<script src="site_libs/tocify-1.9.1/jquery.tocify.js"></script>
<script src="site_libs/navigation-1.1/tabsets.js"></script>
<link href="site_libs/highlightjs-9.12.0/default.css" rel="stylesheet" />
<script src="site_libs/highlightjs-9.12.0/highlight.js"></script>
<link href="site_libs/font-awesome-5.1.0/css/all.css" rel="stylesheet" />
<link href="site_libs/font-awesome-5.1.0/css/v4-shims.css" rel="stylesheet" />

<style type="text/css">code{white-space: pre;}</style>
<style type="text/css">
  pre:not([class]) {
    background-color: white;
  }
</style>
<script type="text/javascript">
if (window.hljs) {
  hljs.configure({languages: []});
  hljs.initHighlightingOnLoad();
  if (document.readyState && document.readyState === "complete") {
    window.setTimeout(function() { hljs.initHighlighting(); }, 0);
  }
}
</script>



<style type="text/css">
h1 {
  font-size: 34px;
}
h1.title {
  font-size: 38px;
}
h2 {
  font-size: 30px;
}
h3 {
  font-size: 24px;
}
h4 {
  font-size: 18px;
}
h5 {
  font-size: 16px;
}
h6 {
  font-size: 12px;
}
.table th:not([align]) {
  text-align: left;
}
</style>

<link rel="stylesheet" href="styles.css" type="text/css" />



<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
code {
  color: inherit;
  background-color: rgba(0, 0, 0, 0.04);
}
img {
  max-width:100%;
  height: auto;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
</style>


<style type="text/css">
/* padding for bootstrap navbar */
body {
  padding-top: 60px;
  padding-bottom: 40px;
}
/* offset scroll position for anchor links (for fixed navbar)  */
.section h1 {
  padding-top: 65px;
  margin-top: -65px;
}
.section h2 {
  padding-top: 65px;
  margin-top: -65px;
}
.section h3 {
  padding-top: 65px;
  margin-top: -65px;
}
.section h4 {
  padding-top: 65px;
  margin-top: -65px;
}
.section h5 {
  padding-top: 65px;
  margin-top: -65px;
}
.section h6 {
  padding-top: 65px;
  margin-top: -65px;
}
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #ffffff;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script>
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark it active
  menuAnchor.parent().addClass('active');

  // if it's got a parent navbar menu mark it active as well
  menuAnchor.closest('li.dropdown').addClass('active');
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  background: white;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before {
  content: "";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "&#xe258;";
  border: none;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open')
  });
});
</script>

<!-- code folding -->



<script>
$(document).ready(function ()  {

    // move toc-ignore selectors from section div to header
    $('div.section.toc-ignore')
        .removeClass('toc-ignore')
        .children('h1,h2,h3,h4,h5').addClass('toc-ignore');

    // establish options
    var options = {
      selectors: "h1,h2,h3",
      theme: "bootstrap3",
      context: '.toc-content',
      hashGenerator: function (text) {
        return text.replace(/[.\\/?&!#<>]/g, '').replace(/\s/g, '_').toLowerCase();
      },
      ignoreSelector: ".toc-ignore",
      scrollTo: 0
    };
    options.showAndHide = true;
    options.smoothScroll = true;

    // tocify
    var toc = $("#TOC").tocify(options).data("toc-tocify");
});
</script>

<style type="text/css">

#TOC {
  margin: 25px 0px 20px 0px;
}
@media (max-width: 768px) {
#TOC {
  position: relative;
  width: 100%;
}
}


.toc-content {
  padding-left: 30px;
  padding-right: 40px;
}

div.main-container {
  max-width: 1200px;
}

div.tocify {
  width: 20%;
  max-width: 260px;
  max-height: 85%;
}

@media (min-width: 768px) and (max-width: 991px) {
  div.tocify {
    width: 25%;
  }
}

@media (max-width: 767px) {
  div.tocify {
    width: 100%;
    max-width: none;
  }
}

.tocify ul, .tocify li {
  line-height: 20px;
}

.tocify-subheader .tocify-item {
  font-size: 0.90em;
}

.tocify .list-group-item {
  border-radius: 0px;
}


</style>



</head>

<body>


<div class="container-fluid main-container">


<!-- setup 3col/9col grid for toc_float and main content  -->
<div class="row-fluid">
<div class="col-xs-12 col-sm-4 col-md-3">
<div id="TOC" class="tocify">
</div>
</div>

<div class="toc-content col-xs-12 col-sm-8 col-md-9">




<div class="navbar navbar-default  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">Home</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="about.html">About</a>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" aria-expanded="false">
    Topics
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="LF1.html">LF1</a>
    </li>
    <li>
      <a href="LF2.html">LF2</a>
    </li>
    <li>
      <a href="LF3.html">LF3</a>
    </li>
  </ul>
</li>
<li>
  <a href="mailto:&lt;rh2616@cumc.columbia.edu&gt;">
    <span class="fa fa-envelope fa-lg"></span>
     
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div class="fluid-row" id="header">



<h1 class="title toc-ignore">Topic III - LF1</h1>

</div>


<div id="ca-pregnancy-associated" class="section level2">
<h2>ca pregnancy associated</h2>
<p>(a)<img src="images/LF1/ca_pregnancy_associated/a1a.tif" style="width:21%"> (b)<img src="images/LF1/ca_pregnancy_associated/a1b.tif" style="width:21%"> (c)<img src="images/LF1/ca_pregnancy_associated/a1c.tif" style="width:21%"> (d)<img src="images/LF1/ca_pregnancy_associated/a1d.tif" style="width:21%"></p>
<p>Figure 1 - Invasive ductal carcinoma (IDC) in a pregnant patient on mammography a) MLO b) CC c,d) spot compression views of the right breast demonstrates an obscured mass in the medial right breast (arrows).</p>
<p>(a)<img src="images/LF1/ca_pregnancy_associated/a2a.tif" style="width:21%"> (b)<img src="images/LF1/ca_pregnancy_associated/a2b.tif" style="width:21%"> (c)<img src="images/LF1/ca_pregnancy_associated/a2c.tif" style="width:21%"> (d)<img src="images/LF1/ca_pregnancy_associated/a2d.tif" style="width:21%"></p>
<p>Figure 2 - IDC on ultrasound in a pregnant patient</p>
<ol style="list-style-type: lower-alpha">
<li>Grayscale and</li>
<li>color Doppler evaluation of the right breast demonstrates an irregular hypoechoic mass with internal vascularity corresponding to the mammographic and palpable abnormality c,d) Prominent lymph nodes (arrows) with thickened cortices were identified in the axilla on grayscale and color Doppler images. The mass was biopsied under ultrasound, yielding invasive ductal carcinoma, NOS, poorly differentiated.</li>
</ol>
<p>(a)<img src="images/LF1/ca_pregnancy_associated/a1a.tif" style="width:28%"> (b)<img src="images/LF1/ca_pregnancy_associated/a1b.tif" style="width:28%"> (c)<img src="images/LF1/ca_pregnancy_associated/a1c.tif" style="width:28%"></p>
<p>Figure 3 - IDC in a pregnant patient on MRI performed for extent of disease evaluation</p>
<ol style="list-style-type: lower-alpha">
<li>Sagittal T2-weighted FS image demonstrates marked hyperintensity of the glandular tissue related to lactation b,c) Sagittal T1-weighted FS post-contrast images demonstrate enlarged right axillary lymph nodes (arrow heads) and an irregular round necrotic mass (arrows) corresponding to the known malignancy with washout kinetics on CAD analysis (not shown).</li>
</ol>
<p><strong>Teaching Points</strong>:</p>
<p>Pregnancy associated breast carcinoma (PABC) is a rare occurrence with an estimated frequency of 2.3 cases per 100,000 deliveries and represents up to 3% of all breast malignancies. The diagnosis of breast cancer during pregnancy is a challenging situation for the patient and the clinician because it involves both the mother and the fetus. The hormone-induced changes that occur in breast tissue during pregnancy and lactation is a major cause of delay in diagnosis of PABC, therefore, resulting in poorer outcome. Given its high sensitivity compared to mammography, ultrasound is considered the initial imaging test in symptomatic pregnant or lactating women. However, mammography should be almost always performed in adjunct to ultrasound to evaluate for the presence of accompanying features of malignancy such as microcalcifications. The radiologic features of PABC are similar to those of non-PABC. MR imaging in pregnant women should not be used routinely, although there is no known adverse effect of MRI on the fetus. In lactating women, the breast parenchyma shows diffuse increased signal intensity on the T2-weighted images due to the fraction of mobile water in milk. Following contrast administration, lactational parenchyma demonstrates an initial rapid enhancement and a subsequent early plateau of enhancement. Tumors can be well visualized on the T2W sequence is these patients.</p>
<p><em>References</em>:</p>
<ol style="list-style-type: decimal">
<li>Cordoa O, Llurba E, Saura C, et al. Multidisciplinary approach to reast cancer diagnosed during pregnancy: Maternal and neonatal outcomes. The Breast 22(2013) 515-519.</li>
<li>Sabate J M, Clotet M, Torrubia S, et al. Radiologic Evaluation of Breast Disorders Related to Pregnancy and Lactation. Radiographic 2007; 27:S101-S124.</li>
<li>Vashi R, Hooley, R, Butler R, et al. Breast Imaging of the Pregnant and Lactating Patient: Physiologic Changes and Common Benign Entities. American Journal of Roentgenology: 2013; 200: 329-336.</li>
<li>ACR PRACTICE PARAMETER FOR PERFOMRNG AND INTERPRETING MRI. Amended 2014.</li>
</ol>
</div>
<div id="ca-neo-adj-partial-response-2-x" class="section level2">
<h2>ca neo adj partial response 2 x</h2>
<p>(a)<img src="images/LF1/ca_neoadj_pr/a1A.tif" style="width:40%"> (b)<img src="images/LF1/ca_neoadj_pr/a1B.tif" style="width:40%"> Figure 1 - MRI of newly diagnosed left breast invasive ductal carcinoma with axillary lymph node metastases</p>
<ol style="list-style-type: lower-alpha">
<li>Sagittal post-contrast subtraction image of the left breast demonstrates segmental non-mass enhancement (arrows) measuring up to 6.2 cm in the upper left breast with associated localizing clip artifact (arrowhead) from a biopsy which yielded invasive ductal carcinoma</li>
<li>This area is predominantly colored red on the corresponding CAD enhancement kinetics overlay, indicating rapid uptake and washout.</li>
</ol>
<p>(a)<img src="images/LF1/ca_neoadj_pr/a2A.tif" style="width:40%"> (b)<img src="images/LF1/ca_neoadj_pr/a2B.tif" style="width:40%"></p>
<p>Figure 2 - 5 month follow-up MRI following neoadjuvant chemotherapy</p>
<ol style="list-style-type: lower-alpha">
<li>Sagittal post-contrast subtraction image of the left breast at the location of the localizing clip (arrowhead) shows reduction of non-mass enhancement (arrows), now measuring up to 2.8 cm</li>
<li>The CAD enhancement kinetics overlay now shows the area to be predominantly blue, indicating mild uptake and progressive enhancement. Enlarged axillary lymph nodes from known metastatic disease had also decreased in size and resumed their normal morphology (not shown). Surgical pathology at the time of lumpectomy showed residual tumor measuring up to 2.5 cm and 2 positive axillary lymph nodes.</li>
</ol>
<p><strong>Teaching points</strong>:</p>
<p>In patients undergoing neoadjuvant therapy, breast MRI provides the best correlation with final surgical pathology compared to physical examination, mammography, and sonography and is one of the generally accepted indications for getting a breast MRI evaluation. However, MRI may overestimate or underestimate residual disease in approximately 29% of the patients. Neoadjuvant treatment can be effective in reducing locally advanced tumor and in certain cases breast conservation can become a surgical treatment option rather than mastectomy. In patients with a good response, in addition to the reduction in size of tumor, change in enhancement pattern to persistent from washout pattern as well overall decrease in the amount of background parenchymal enhancement have been noted, as illustrated in this case.</p>
<p><em>References</em>:</p>
<ol style="list-style-type: decimal">
<li>Yeh E, Slanetz P, Kopans D, Prospective Comparison of Mammography, Sonography, and MRI in Patients Undergoing Neoadjuvant Chemotherapy for Palpable Breast Cancer AJR. 2005;184: 868-877.</li>
<li>Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Sudilovsky D, Hylton NM. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. AJR 2002; 179:1193-1199</li>
<li>Eisenhauer EA, Therasse P, Bogaerts J, et al.(2009) New Response Evaluation Criteria in Solid Tumours: Revised RECIST guideline (version 1.1) Eur J Cancer 45:228–247.</li>
</ol>
</div>
<div id="ca-pagets-dz" class="section level2">
<h2>ca paget’s dz</h2>
<p>(a)<img src="images/LF1/ca_pagets_dz/a1A.tif" style="width:21%"> (b)<img src="images/LF1/ca_pagets_dz/a1B.tif" style="width:21%"> (c)<img src="images/LF1/ca_pagets_dz/a1C.tif" style="width:21%"> (d)<img src="images/LF1/ca_pagets_dz/a1D.tif" style="width:21%"></p>
<p>Figure 1 - Paget’s disease with additional disease detected on MRI</p>
<ol style="list-style-type: lower-alpha">
<li>Axial T1-weighted and<br />
</li>
<li>axial T2-weighted FS images demonstrate T1 hypointensity and mild T2 hyperintensity of the right nipple (arrow), as well as marked retroareolar T2 hyperintensity (arrows)</li>
<li>Axial post-contrast subtraction with corresponding</li>
<li>CAD images demonstrate marked enhancement of the nipple (arrow) with mixed enhancement kinetics (arrow) and additional linear non mass enhancement posterior to the nipple (arrowhead).</li>
</ol>
<p>(a)<img src="images/LF1/ca_pagets_dz/a2a.tif" style="width:21%"> (b)<img src="images/LF1/ca_pagets_dz/a2b.tif" style="width:21%"> (c)<img src="images/LF1/ca_pagets_dz/a2c.tif" style="width:21%"> (d)<img src="images/LF1/ca_pagets_dz/a2d.tif" style="width:21%"></p>
<p>Figure 2 - Paget’s diseaseon mammography</p>
<ol style="list-style-type: lower-alpha">
<li>Right MLO and</li>
<li>CC views with c,d) corresponding retroareolar spot magnification views demonstrate a suspicious group of mildly pleomorphic calcifications (arrows), which yielded ductal carcinoma in situ on biopsy.</li>
</ol>
<p><strong>Teaching Points</strong>:</p>
<p>Paget Disease is a rare disease of the breast, accounting for 1-3% of all breast cancer cases. The disease is characterized by involvement of the nipple-areolar complex with malignant cells called Paget cells. This is manifested clinically by nipple/areolar itching, erythema, scaly skin, bloody nipple discharge, nipple erosion, ulceration, or retraction. Diagnosis is usually made by a full thickness punch biopsy of the nipple-areolar complex. Paget’s disease of the breast is nearly always a sign of underlying breast malignancy with most studies reporting the presence of a concurrent ductal carcinoma in situ or invasive cancer, in over 90% of patients. Approximately 50% of patients with Paget disease also present with an associated palpable mass in the breast,90% of which are found to have invasive disease, whereas a lesion without a palpable mass is usually associated with DCIS. On Mammography, Paget disease can be seen as nipple/areolar abnormalities such as skin thickening, malignant calcifications or discrete lesions involving the nipple areolar complex or breast parenchyma. However, mammograms can appear completely normal in up to 50% of patients with Paget disease, therefore, correlation with clinical examination is considered critical. MR imaging is usually performed to detect underlying occult malignancy. Common MR findings of Paget disease include, asymmetric nipple enhancement and nodularity with or without associated features of DCIS and invasive carcinoma.</p>
<p><em>References</em>:</p>
<ol style="list-style-type: decimal">
<li>Lim H S, Jeong S J, Lee J S, et al. Paget Disease of the Breast: Mammographic, US, and MR Imaging Findings with Pathologic Correlation. RadioGraphics 2011; 31:1973–1987</li>
<li>Kim HS, Seok JH, Cha ES, et al. Significance of nipple enhancement of Paget’s disease in contrast enhanced breast MRI. Arch Gynecol Obstet.2010 Aug; 282(2):157-62.</li>
<li>Muttarak M, Siriya B, Kongmebhol P, et al. Paget’s disease of the breast: clinical, imaging and pathologic findings: a review of 16 patients Biomed Imaging Interv J 2011; 7(2):e16</li>
</ol>
</div>
<div id="ca-pectoralis" class="section level2">
<h2>ca pectoralis</h2>
<p>(a)<img src="images/LF1/ca_pectoralis/a1a.tif" style="width:21%"> (b)<img src="images/LF1/ca_pectoralis/a1b.tif" style="width:21%"> (c)<img src="images/LF1/ca_pectoralis/a1c.tif" style="width:21%"> (d)<img src="images/LF1/ca_pectoralis/a1d.tif" style="width:21%"></p>
<p>Figure 1 - Left breast cancer with pectoralis muscle involvement</p>
<ol style="list-style-type: lower-alpha">
<li>Sagittal T1-weighted FS image demonstrates an irregular mass (arrows) abutting the pectoralis major muscle (arrow-heads). Skin thickening is noted (arrow-heads) b,c,d) Selected sagittal post-contrast subtraction images demonstrate irregular homogeneously and heterogeneously enhancing masses (arrows) in the posterior third of the breast, some of which abut the expanded, enhancing pectoralis major muscle (arrow-heads).</li>
</ol>
<p><strong>Teaching Points</strong>:</p>
<p>MRI evaluation of breast carcinoma prior to surgical treatment may be useful in both mastectomy and breast conservation candidates to define the relationship of the tumor to the fascia and its extension into pectoralis major and chest wall. Invasion of the pectoralis muscle is either infiltrative or mass-like which should be easily distinguishable from smooth baseline muscle enhancement. Obliteration of the fat plane between tumor and muscle alone does not indicate muscle involvement. There must be associated focal enhancement of the muscle. The patient with tumor extension into the chest wall is usually considered stage T4 according to TNM classification and stage IIIB, which requires chest wall resection. Whereas invasion of the pectoralis major muscle alone, does not affect staging and may only require muscle resection at the time of surgery.</p>
<p><em>References</em>:</p>
<ol style="list-style-type: decimal">
<li>Morris EA, Schwartz LH, Drotman MB, et al. Evaluation of pectoralis major muscle in patients with posterior breast tumors on breast MR images: early experience. Radiology 2000;214:67-72</li>
<li>ACR PRACTICE PARAMETER FOR THE PERFORMANCE OF CONTRASTENHANCED MAGNETIC RESONANCE IMAGING (MRI) OF THE BREAST. Amended 2014 (Resolution 39).</li>
</ol>
</div>
<div id="ca-stage-3-c-inop" class="section level2">
<h2>ca stage 3 c inop</h2>
<p>(a)<img src="images/LF1/ca_stage3cinop/a1a.tif" style="width:28%"> (b)<img src="images/LF1/ca_stage3cinop/a1b.tif" style="width:28%"> (c)<img src="images/LF1/ca_stage3cinop/a1c.tif" style="width:28%"></p>
<p>Figure 1 - MRI performed to evaluate extent of disease in a patient with newly diagnosed left breast invasive ductal carcinoma</p>
<ol style="list-style-type: lower-alpha">
<li>Sagittal post-contrast subtraction image of the left breast</li>
<li>axial T1-weighted FS post-contrast image of both breasts</li>
<li>axial T2-weighted FS image of both breasts demonstrate a mildly T2 hyperintense, heterogeneously enhancing, irregular, spiculated mass (arrows) extending anteriorly to the skin surface with nipple retraction and posteriorly to the pectoralis major muscle (arrowheads). This was staged as T4c according to the TNM classification system.</li>
</ol>
<p>(a)<img src="images/LF1/ca_stage3cinop/a2a.tif" style="width:28%"> (b)<img src="images/LF1/ca_stage3cinop/a2b.tif" style="width:28%"> (c)<img src="images/LF1/ca_stage3cinop/a2c.tif" style="width:28%"></p>
<p>Figure 2 - Corresponding left mammogram and ultrasound images</p>
<ol style="list-style-type: lower-alpha">
<li>CC and</li>
<li>MLO views demonstrate an irregular, spiculated, hyperdense mass (arrows) in the central left breast with associated architectural distortion</li>
<li>Left breast ultrasound shows a shadowing irregular hypoehcoic mass (calipers) corresponding to the mass shown on MRI and mammography</li>
</ol>
<p>(a)<img src="images/LF1/ca_stage3cinop/a3a.tif" style="width:40%"> (b)<img src="images/LF1/ca_stage3cinop/a3b.tif" style="width:40%"> Figure 3 - Corresponding PET/CT images</p>
<ol style="list-style-type: lower-alpha">
<li>Axial CT and fused PET/CT images corroborate the findings with a large hypermetabolic left breast mass (teal oval) shown involving the underlying pectoralis major muscle</li>
<li>Coronal PET MIP image shows both thea hypermetabolic left breast mass (arrow) and a hypermetabolic ipsilateral supraclavicular lymph node (arrowhead). This was classified as N3c.</li>
</ol>
<p><strong>Teaching Points</strong>:</p>
<p>Two patterns of Pectoralis muscle involvement have been noted: infiltrative enhancement pattern with preservation of muscular architecture and a mass-like enhancement that expanded the pectoralis major muscle with loss of the muscle striations. As discussed earlier, invasion of the pectoralis major muscle alone does not affect staging and may only require muscle resection at the time of surgery. However, in our demonstrated case, the spiculated mass appears to extend posteriorly into the pectoralis muscles as well as the chest wall. Given the positive ipsilateral supraclavicular lymph node, final stage was IIIC which is a non-operable stage with N3c classification.</p>
<p><em>References</em>: 1) Morris EA, Schwartz LH, Drotman MB, et al. Evaluation of pectoralis major muscle in patients with posterior breast tumors on breast MR images: early experience. Radiology 2000;214:67-72] 2) Lee SC, Jain PA, Jethwa SC, et al. Radiologists’ Role in Breast Cancer Staging: Providing Key Information for Clinicians. RadioGraphics 2014; 34:330–342</p>
</div>
<div id="ca-stage-4-liver-met-idc-lad" class="section level2">
<h2>ca stage 4 liver met IDC LAD</h2>
<p>(a)<img src="images/LF1/ca_stage4livermet/a1a.tif" style="width:28%"> (b)<img src="images/LF1/ca_stage4livermet/a1b.tif" style="width:28%"> (c)<img src="images/LF1/ca_stage4livermet/a1c.tif" style="width:28%"></p>
<p>(d)<img src="images/LF1/ca_stage4livermet/a1d.tif" style="width:28%"> (e)<img src="images/LF1/ca_stage4livermet/a1e.tif" style="width:28%"></p>
<p>Figure 1 - MRI and CT performed to evaluate for extent of disease in a patientwith biopsy proven xxx breast invasive ductal carcinoma a,b) Sagittal post-contrast subtraction images demonstrate an irregular heterogeneously enhancing mass (arrows) with central necrosis. Enlarged axillary lymph nodes (arrow-heads) are noted c) CAD enhancement kinetics analysis demonstrates a predominant washout pattern within the mass d) Axial MRI localizer image and corresponding e) Axial CT image demonstrate metastatic lesions within the liver (arrows).</p>
<p><strong>Teaching Points</strong>: Approximately 4% of patients with a diagnosis of breast cancer will have distant metastases at the time of presentation. Breast MRI localizer images with large FOV can sometimes indicate possible distant metastasis as illustrated in this case, prompting additional dedicated imaging and confirmation biopsy. The most common sites of distant metastasis for breast cancer are bone, lung, brain, and liver. Regardless of tumor size and nodal status, the presence of distant metastases at the time of diagnosis indicates overall stage IV disease which has a 5-year survival rate of approximately 22%.</p>
<p><em>References</em>:</p>
<ol style="list-style-type: decimal">
<li>Lee SC, Jain PA, Jethwa SC, et al. Radiologists’ Role in Breast Cancer Staging: Providing Key Information for Clinicians. RadioGraphics 2014; 34:330–342</li>
</ol>
</div>
<div id="ca-stage-n2-im-node" class="section level2">
<h2>ca stage N2 im node</h2>
<p>(a)<img src="images/LF1/ca_stageN2_im_node/a1a.tif" style="width:21%"> (b)<img src="images/LF1/ca_stageN2_im_node/a1b.tif" style="width:21%"> (c)<img src="images/LF1/ca_stageN2_im_node/a1c.tif" style="width:21%"> (d)<img src="images/LF1/ca_stageN2_im_node/a1d.tif" style="width:21%"></p>
<p>Figure 1 - Breast MRI was performed for extent of disease evaluation in a patient with recently diagnosed right breast cancer</p>
<ol style="list-style-type: lower-alpha">
<li>Post-contrast axial subtraction image demonstrates an enhancing irregular spiculated mass in the posterior right breast (arrows) with</li>
<li>central washout on CAD enhancement kinetics analysis. This corresponds to the known malignancy</li>
<li>A more inferior T1-weighted FS post-contrast image shows a prominent right internal mammary lymph node (arrow)</li>
<li>with mixed enhancement kinetics on CAD analysis. Subsequently, the right internal mammary lymph node was identified on ultrasound and fine needle aspiration was performed yielding adenocarcinoma, compatible with breast cancer metastasis.</li>
</ol>
<p><strong>Teaching Points</strong>: Lymph node status and tumor size are the most important prognostic indicators. Appropriate evaluation of regional lymph node status (N) is important for staging, treatment planning, and prognosis.</p>
<p>According to the seventh edition of the AJCC TNM classification, metastases to less than four non-matted, moveable level I or level II nodes is considered N1 disease. N2 disease, as we see in our case example, is defined as involvement of the ipsilateral internal mammary node in the absence of axillary metastases. This usually occurs in cases of deep or medial breast tumors and it may occur in 1%–5% of breast cancers.</p>
<p><em>References</em>:</p>
<ol style="list-style-type: decimal">
<li>Ecanow JS, Abe H, Newstead GM, et al. Axillary Staging of Breast Cancer: What the Radiologist Should Know. RadioGraphics 2013; 33:1589–1612.</li>
<li>Lee SL, Jain PA, Jethwa SC, et al. Radiologists’ Role in Breast Cancer Staging: Providing Key Information for Clinicians. RadioGraphics 2014; 34:330–342.</li>
<li>Neal CH, Daly CP, Nees AV, Helvie MA. Can preoperative axillary US help exclude N2 and N3 metastatic breast cancer?Radiology 2010;257(2): 335–341.</li>
</ol>
</div>
<div id="ca-stage-n3-im-node" class="section level2">
<h2>ca stage N3 im node</h2>
<p>(a)<img src="images/LF1/ca_stageN3_im_node/a1a.tif" style="width:21%"> (b)<img src="images/LF1/ca_stageN3_im_node/a1b.tif" style="width:21%"> (c)<img src="images/LF1/ca_stageN3_im_node/a1c.tif" style="width:21%"> (d)<img src="images/LF1/ca_stageN3_im_node/a1d.tif" style="width:21%"></p>
<p>Figure 1 - Breast MRI performed for extent of disease evaluation in a patient with newly diagnosed left breast invasive ductal carcinoma a) Axial post-contrast subtraction image shows an irregular 3.5 cm heterogeneously enhancing left breast mass (arrows) with central clip artifact (arrowhead) which yielded invasive ductal carcinoma on biopsy b) A more superior axial post-contrast subtraction image shows a mildly enlarged left axillary lymph node (arrow) which underwent FNA yielding metastasis c) An axial post-contrast subtraction image at another level shows a 1.9 cm heterogeneously enhancing left internal mammary lymph node with areas of hyperintensity on d) the T2-weighted FS image consistent with necrosis.</p>
<p>(a)<img src="images/LF1/ca_stageN3_im_node/a2a.tif" style="width:21%"> (b)<img src="images/LF1/ca_stageN3_im_node/a2b.tif" style="width:21%"> (c)<img src="images/LF1/ca_stageN3_im_node/a2c.tif" style="width:21%"></p>
<p>Figure 2 - Corresponding axial CT and fused PET/CT images</p>
<ol style="list-style-type: lower-alpha">
<li>hypermetabolic index left breast mass (green circle)</li>
<li>the malignant left axillary lymph node (green circle)</li>
<li>the hypermetabolic left internal mammary lymph node (green circle).</li>
</ol>
<p><strong>Teaching points</strong>: Breast MRI can identify abnormal internal mammary lymph nodes that can impact clinical staging, planning of radiation therapy which in case of metastasis would require a wide field of irradiation. The N3 category, which includes metastases in the level III (infraclavicular) and supraclavicular nodal stations, is subdivided into subcategories N3a, N3b, and N3c. N3a includes metastases in the ipsilateral infraclavicular nodes with or without level I-II axillary involvement; N3b, ipsilateral internal mammary lymph node metastases with level I-II axillary nodal involvement; and N3c, ipsilateral supraclavicular lymph node involvement with or without level I-II axillary involvement.</p>
<p>In our case, the patient was found to have an presumed metastatic internal mammary lymph node in addition to level I and II axillary lymph nodes which represents N3b.</p>
<p><em>References</em>:</p>
<ol style="list-style-type: decimal">
<li>Ecanow JS, Abe H, Newstead GM, et al. Axillary Staging of Breast Cancer: What the Radiologist Should Know. RadioGraphics 2013; 33:1589–1612.</li>
<li>Lee SL, Jain PA, Jethwa SC, et al. Radiologists’ Role in Breast Cancer Staging: Providing Key Information for Clinicians. RadioGraphics 2014; 34:330–342.</li>
<li>Neal CH, Daly CP, Nees AV, Helvie MA. Can preoperative axillary US help exclude N2 and N3 metastatic breast cancer?Radiology 2010;257(2): 335–341.</li>
</ol>
</div>
<div id="ca-stage-t4-ilc-nipp" class="section level2">
<h2>ca stage T4 ilc nipp</h2>
<p>(a)<img src="images/LF1/ca_stageT4_ilcnipp/a1a.tif" style="width:28%"> (b)<img src="images/LF1/ca_stageT4_ilcnipp/a1b.tif" style="width:28%"> (c)<img src="images/LF1/ca_stageT4_ilcnipp/a1c.tif" style="width:28%"></p>
<p>Figure 1 - MRI performed to evaluate disease extent in a patient with newly diagnosed left breast invasive lobular carcinoma</p>
<ol style="list-style-type: lower-alpha">
<li>Axial post-contrast subtraction image of both breasts and b,c) sagittal post-contrast subtraction images of the left breast demonstrate a heterogeneously enhancing irregular, spiculated retroareolar left breast mass (arrows) with extension to the nipple (arrowheads).</li>
</ol>
<p>(a)<img src="images/LF1/ca_stageT4_ilcnipp/a2a.tif" style="width:21%"> (b)<img src="images/LF1/ca_stageT4_ilcnipp/a2b.tif" style="width:21%"> (c)<img src="images/LF1/ca_stageT4_ilcnipp/a2c.tif" style="width:21%"> (d)<img src="images/LF1/ca_stageT4_ilcnipp/a2d.tif" style="width:21%"></p>
<p>Figure 2 - Corresponding mammogram Left</p>
<p>a, b) CC and MLO views demonstrate an irregular indistinct hyperdense mass (arrows) in the retroareolar region with extension to the retracted nipple (arrowhead). Spot compression c, d) CC and ML views better depict the tumor extension (arrows) to the retracted nipple (arrowhead)</p>
<p>(a)<img src="images/LF1/ca_stageT4_ilcnipp/a3a.tif" style="width:40%"> (b)<img src="images/LF1/ca_stageT4_ilcnipp/a3b.tif" style="width:40%"></p>
<p>Figure 3 - Corresponding ultrasound</p>
<p>a, b) Grayscale and Color Doppler images demonstrate a taller-than-wide, irregular, indistinct mass with posterior acoustic shadowing in the retroareolar left breast. Internal vascularity is noted.</p>
<p><strong>Teaching Points</strong>: MR imaging has been shown to affect clinical management in up to 50% of patients with ILC, leading to changes in surgical management in 28% of cases. Several published studies indicate pre-operative MRI is helpful in identifying and predicting clinically occult tumor involvement of the NAC. MRI-measured distance from the NAC, tumor size, subareolar/central location (as illustrated in this case) and unilateral enhancement of the nipple with continuous enhancement from the index lesion are correlated with increased risk of NAC involvement.</p>
<p><em>References</em>:</p>
<ol style="list-style-type: decimal">
<li>Steen ST, Chung AP, Han SH, et al. Predicting nipple-areolar involvement using preoperative breast MRI and primary tumor characteristics. Ann Surg Oncol. 2013 Feb;20 (2):633-9.</li>
<li>Lopez JK, Bassett LW. Invasive Lobular Carcinoma of the Breast: Spectrum of Mammographic, US, and MR Imaging Findings. RadioGraphics 2009; 29:165–176.</li>
<li>Mann RM, Hoogeveen YL, Blickman JG, et al. MRI compared to conventional diagnostic work-up in the detection and evaluation of invasive lobular carcinoma of the breast: a review of existing literature. Breast Cancer Res Treat 2008;107(1):1– 14.</li>
</ol>
</div>
<div id="ca-stage-t4-cw" class="section level2">
<h2>ca stage T4 CW</h2>
<p>(a)<img src="images/LF1/ca_stageT4cw/a1a.tif" style="width:21%"> (b)<img src="images/LF1/ca_stageT4cw/a1b.tif" style="width:21%"> (c)<img src="images/LF1/ca_stageT4cw/a1c.tif" style="width:21%"> (d)<img src="images/LF1/ca_stageT4cw/a1d.tif" style="width:21%"></p>
<p>Figure 1 - Bilateral breast MRI was performed on a patient with history of left breast malignancy status post lumpectomy 5 years prior with worsening left chest pain</p>
<ol style="list-style-type: lower-alpha">
<li>Sagittal post-contrast subtraction image of the left breast shows a highly suspicious heterogeneously enhancing mass (arrows) in the posterior left breast involving the chest wall (arrow-heads) and possibly the pleura</li>
<li>CAD kinetic enhancement analysis demonstrates a mixed pattern with central washout</li>
<li>Sagittal post-contrast subtraction image through the right axilla shows an abnormally enlarged lymph node (arrows)</li>
<li>with predominant washout kinetics on CAD enhancement kinetics anaylsis, suspicious for metastasis. Biopsy of the left chest wall mass and contralateral axillary lymph node yielded recurrent invasive ductal carcinoma with metastasis to the contralateral lymph node.</li>
</ol>
<p><strong>Teaching Points</strong>:</p>
<p>MRI evaluation of breast carcinoma prior to surgical treatment may be useful in both mastectomy and breast conservation candidates to define the relationship of the tumor to the fascia and its extension into pectoralis major and chest wall. Invasion of the pectoralis muscle is either infiltrative or mass-like which should be easily distinguishable from smooth baseline muscle enhancement. Obliteration of the fat plane between tumor and muscle alone does not indicate muscle involvement. The patient with tumor extension into the chest wall is usually considered stage T4 according to TNM classification and stage IIIB, which requires chest wall resection. Whereas invasion of the pectoralis major muscle alone, does not affect staging and may only require muscle resection at the time of surgery.</p>
<p><em>References</em>:</p>
<ol style="list-style-type: decimal">
<li><p>Morris EA, Schwartz LH, Drotman MB, et al. Evaluation of pectoralis major muscle in patients with posterior breast tumors on breast MR images: early experience. Radiology 2000;214:67-72</p></li>
<li><p>ACR PRACTICE PARAMETER FOR THE PERFORMANCE OF CONTRASTENHANCED MAGNETIC RESONANCE IMAGING (MRI) OF THE BREAST. Amended 2014 (Resolution 39).</p></li>
</ol>
</div>
<div id="ca-trip-neg" class="section level2">
<h2>ca trip neg</h2>
<p>(a)<img src="images/LF1/ca_tripneg/a1a.tif" style="width:40%"> (b)<img src="images/LF1/ca_tripneg/a1b.tif" style="width:40%"></p>
<p>Figure 1 - Triple negative infiltrating ductal carcinoma (IDC) on mammography</p>
<ol style="list-style-type: lower-alpha">
<li>Left MLO view demonstrates an obscured oval mass (arrows) at the superior aspect of the breast, middle depth, which is better seen on</li>
<li>spot compression</li>
</ol>
<p>(a)<img src="images/LF1/ca_tripneg/a2a.tif" style="width:28%"> (b)<img src="images/LF1/ca_tripneg/a2b.tif" style="width:28%"> (c)<img src="images/LF1/ca_tripneg/a2c.tif" style="width:28%"></p>
<p>(d)<img src="images/LF1/ca_tripneg/a2d.tif" style="width:28%"> (e)<img src="images/LF1/ca_tripneg/a2e.tif" style="width:28%"></p>
<p>Figure 2 - Triple negative IDC on MRI</p>
<ol style="list-style-type: lower-alpha">
<li>Sagittal T1-weighted FS image shows an oval lobulated heterogeneous mass (arrows) in the superior aspect of the breast, with</li>
<li>Corresponding T2 isointensity and central T2 hyperintensity. Metallic artifact from a biopsy clip is best appreciated on the T1 image</li>
<li>Sagittal T1-weighted FS post-contrast image shows thick heterogeneous rim enhancement (arrows) with inferocentral non-enhancement corresponding to the T2 hyperintenstity, signifying central necrosis</li>
<li>CAD analysis demonstrates mixed enhancement kinetics with a predominant washout pattern in the viable portions of the tumor and non-enhancement in the central necrotic portion</li>
<li>Sagittal T1-weightedFS post contrast image of the left axilla shows axillary lymphadenopathy.</li>
</ol>
<p>Figure 3 - Triple negative IDC on ultrasound</p>
<ol style="list-style-type: lower-alpha">
<li>Targeted ultrasound of the left breast mass shows an oval hypoechoic mass with a central anechoic region (arrow), correlating with the central necrosis on MRI</li>
<li>Targeted ultrasound of the left axilla shows an abnormal lymph node with irregular cortical thickening</li>
</ol>
<p><strong>Teaching Points</strong>:</p>
<p>Triple Receptor Negative Cancer is a distinctive subgroup of breast cancer that is negative for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), accounting for 11-20% of all breast cancer types. It’s associated with basal molecular subtype. Patients with triple negative tumors have poorer clinical outcome with higher rates of recurrence and distant metastasis. Sonographically, triple negative tumors can mimic benign fibroadenoma or a complicated cyst. MR imaging, usually presents as a unifocal necrotic mass with heterogeneous rim enhancement, and central high signal intensity on T2-weighted representing necrotic content as in this case.</p>
<p><em>References</em>:</p>
<ol style="list-style-type: decimal">
<li>Uematsu T, Kasami M, Yuen S. Triple-Negative Breast Cancer: Correlation between MR Imaging and Pathologic Findings. Radiology: Volume 250: Number 3—March 2009.</li>
<li>Dogan BE, Turnbull LW. Imaging of triple-negative breast cancer. Annals of Oncology 23 (supplement 6): vi23-vi29, 2012.</li>
<li>Krismanich-Conniff K, Paramgul C, Patterson SK, et al. Triple Receptor-Negative Breast Cancer: Imaging and Clinical Characteristics. AJR 2012; 198:458–464</li>
</ol>
</div>
<div id="ca-tabular" class="section level2">
<h2>ca tabular</h2>
<p>(a)<img src="images/LF1/ca_tubular/a1a.tif" style="width:40%"> (b)<img src="images/LF1/ca_tubular/a1b.tif" style="width:40%"></p>
<p>Figure 1 - Initial MRI images obtained in a patient with tubular carcinoma detected on high risk screening MRI follow-up</p>
<ol style="list-style-type: lower-alpha">
<li>Sagittal T1-weighted FS post-contrast image shows a focus of enhancement along the posterior right 12:00 axis (arrow)</li>
<li>CAD enhancement kinetic analysis demonstrates a mixed pattern (arrow), with predominantly progressive and plateau kinetics</li>
</ol>
<p>(a)<img src="images/LF1/ca_tubular/a2a.tif" style="width:28%"> (b)<img src="images/LF1/ca_tubular/a2b.tif" style="width:28%"> (c)<img src="images/LF1/ca_tubular/a2c.tif" style="width:28%"></p>
<p>Figure 2 - 12-month follow-up MRI images demonstrating tubular carcinoma</p>
<ol style="list-style-type: lower-alpha">
<li>Sagittal T2-weighted FS image of the right breast shows minimal T2 hyperintensity (arrow) in the posterior breast</li>
<li>Sagittal post-contrast subtraction image shows interval enlargement of the previously seen enhancing focus, which is now a heterogeneously enhancing, irregular, spiculated mass in the posterior right breast</li>
<li>CAD enhancement kinetics analysis shows a mixed enhancement pattern, predominantly washout, suspicious for malignancy. Biopsy yielded tubular carcinoma.</li>
</ol>
<p><strong>Teaching Points</strong>:</p>
<p>Tubular carcinoma of the breast is a well-differentiated form of invasive ductal carcinoma. It typically occurs in young women aged middle to late 40s and tends to have a more favorable prognosis than other breast cancers. Pure tubular carcinoma is rare and accounts for less than 2% of all breast cancers. Although it may contain other histologic elements, a minimum percentage of tubular elements required to make the diagnosis of tubular carcinoma ranges from 75% to 90%. Tubular carcinoma is often detected as a small spiculated mass on screening mammography, usually less than 1 cm, however it may be discovered as a palpable mass. Those spicules correspond to reactive stroma spreading out of the neoplasm. On MRI, tubular carcinoma appears similar to invasive ductal carcinoma-not otherwise specified with variable kinetic enhancement pattern.</p>
<p><em>References</em>:</p>
<ol style="list-style-type: decimal">
<li>Elson BC, Helvie MA, Frank TS, et al. Tubular carcinoma of the breast: mode of presentation, mammographic appearance and frequency of nodal metastases. AJR 1993; 161: 1173-1176.</li>
<li>Linda A, Zuiani C, Girometti R, et al. Unusual malignant tumors of the breast: MRI features and pathologic correlation. European Journal of Radiology 75 (2010) 178–184.</li>
<li>Kitagawa K, Sakuma H, Ishida N, et al. Contrast-Enhanced High-Resolution MRI of Invasive Breast Cancer: Correlation with Histopathologic Subtypes. AJR 2004;183:1805–1809</li>
</ol>
</div>



</div>
</div>

</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.header').parent('thead').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
